• Рекомендации Европейского клуба прогестинов по профилактике и лечению гестагенами угрожающего или привычного невынашивания беременности
До змісту

Рекомендации Европейского клуба прогестинов по профилактике и лечению гестагенами угрожающего или привычного невынашивания беременности

HEALTH OF WOMAN.2015.6(102):29–31

Рекомендации Европейского клуба прогестинов по профилактике и лечению гестагенами угрожающего или привычного невынашивания беременности

Schindler Аdolf E., Carp Howard, Druckmann Rene, Genazzani Andrea R., Huber Johannes, Pasqualini Jorge, Schweppe Karl W., Szekeres-Bartho Julia

Institute for Medical Research and Education, University Clinic, Essen, Germany, 
Department of Obstetrics & Gynecology, Sheba Medical Center, Tel Hashomer, Israel,
 
Department of Gynecology, ANEMO – Menopausecenter, Nice, France
 
Department of Obstetrics and Gynecology, University of Pisa, Pisa, Italy
 
Department of Obstetrics and Gynecology, Division of Gynecologic Endocrinology and Reproductive Medicine, University of Vienna, Vienna, Austria
 
Hormones and Cancer Research Unit, Paris, France
 
Endometriosis Center Ammerland, Westerstede, Germany
 
Department of Medical Microbiology and Immunology, Medical School Pecs University, Pecs, Hungary
 
Gynecol Endocrinol, Early Online: 1–3. Адаптировано – С.А. Шурпяк

Эти рекомендации разработаны группой европейских экспертов и основаны на данных клинических исследований. Основная цель их создания – обобщить все доступные доказательства в общие рекомендации по профилактике или лечению невынашивания беременности, которые дадут гинекологам, акушерам и специалистам репродуктивной медицины инструкцию касательно профилактики и лечения в интересах сохранения беременностей. Это связано с тем, что ряд заявлений, мнений и рекомендаций уже опубликованных ранее по этой теме, не полностью согласованы между собой.

Ключевые слова: выкидыш, профилактика, прогестагены.

Литература: 
1. Royal College of Obstetricians and Gynaecologists. The investigation and treatment of couples with recurrent first-trimester and second-trimester miscarriage. Guideline no. 17. London, UK. 2011.

2. Indonesian Obstetric and Gynecological Society (HIFERI-POGI). Methodological guidelines for recurrent miscarriage. Jakarta. 2011.

3. Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG). Progeste-rone support of the luteal phase and the first trimester. 2013. Available from: http:// www.ranzcog.edu.au/doc/progesterone-support-of-the-luteal-phase- and-early-pregnancy.html.

4. Practice Committee of American Society of Reproductive Medicine (ASRM). Definition of infertility and recurrent pregnancy loss. Fertil Steril 2013. 99:63. http://dx.doi.org/10.1016/j.fertnstert.2012.09.023; PMid:23095139

5. National Institute for Health and Care Excellence (NICE) Clinical Guideline 154. Ectopic pregnancy and miscarriage. 2012, Dec. Available from: http://guidance.nice.org.uk/cg154.

6. National Institute for Health and Care Excellence (NICE). Miscarriage Clinical Knowledge Summaries. 2013, Jul. Available from: http://cks.nice.org.uk/miscarriage.

7. Saudi Society of Obstetrics and Gynecology Guidelines (SOGS). National Guidelines for prevention and treatment of miscarriages. Saudi J Obstet Gynecol 15:40–63. 2014.

8. Coppola PT, Coppola M. 2003. Vaginal bleeding in the first 20 weeks of pregnancy. Emerg Med Clin North Am 21:667–77. http://dx.doi.org/10.1016/S0733-8627(03)00041-5

9. Schindler AE. 2004. First trimester endocrinology: consequences for diagnosis and treatment of pregnancy failure. Gynecol Endocrinol 18:51–7. http://dx.doi.org/10.1080/09513590310001651795http://dx.doi.org/10.1080/09513590410001725495; PMid:15106366

10. Schindler AE. 2010. Progestogens for treatment and pregnancy disorders. Horm Mol Biol Clin Invest 3:453–460. http://dx.doi.org/10.1515/hmbci.2010.069; PMid:25961219

11. Macklon NS, Geraedts JP, Fauser BC. 2002. Conception to ongoing pregnancy: the ‘black box’ of early pregnancy loss. Hum Reprod Update 8:333–43. http://dx.doi.org/10.1093/humupd/8.4.333; PMid:12206468

12. Everett C. 1997. Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study from general practice. BMJ 351:32–4. http://dx.doi.org/10.1136/bmj.315.7099.32

13. Blois SM, Joachim R, Kandil J et al. 2004. Debletion of CD8+Cells abolishes the pregnancy protective effect of progesterone substitu- tion with dydrogesterone in mice by altering the Th1/Th2 profile. J Immunology 172:5893–9. http://dx.doi.org/10.4049/jimmunol.172.10.5893

14. Wahabi HA, Abed Althagafi NF, Elawad M. 2007. Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev. 18:CD005943. http://dx.doi.org/10.1002/14651858.cd005943.pub2

15. Wahabi HA, Fayed AA, Esmaeil SA, Al Zeidan RA. 2011. Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev. 12:CD005943. http://dx.doi.org/10.1002/14651858.cd005943.pub3

16. Gerhard I, Gwinner B, Eggert-Kruse W, Runnebaum B. 1987. Double blind controlled trial of progesterone substitution in threatened abortion. Bio Res Preg Perinatol. 8:26–34. PMid:2437967

17. Palagiano A, Bulletti C, Pace MC et al. 2004. Effects of vaginal progesterone on pain and uterine contractility in patients with threatened abortion before twelve weeks of pregnancy. Ann NY Acad Sci. 1034:200–10. http://dx.doi.org/10.1196/annals.1335.022; PMid:15731312

18. El-Zibdeh MY, Yousef LT. 2009. Dydrogesterone support in threatened miscarriage. Maturitas 65:S43–6. http://dx.doi.org/10.1016/j.maturitas.2009.11.013; PMid:20007011

19. Pandian RU. 2009. Dydrogesterone in threatened miscarriage: a Malaysian experience. Maturitas 65:S47–50. http://dx.doi.org/10.1016/j.maturitas.2009.11.016; PMid:20005647

20. Carp H. 2012. A systematic review of dydrogesterone for the treatment of threatened miscarriage. Gynecol Endocrinol. 28:983–90. 21. http://dx.doi.org/10.3109/09513590.2012.702875; PMid:22794306 PMCid:PMC3518297

21. Haas DM, Ramsey PS. 2013. Progestogen for preventing miscarriage. Cochrane Database Syst Rev. 10:CD003511. http://dx.doi.org/10.1002/14651858.cd003511.pub3

22. El-Zibdeh MY. 2005. Dydrogesterone in the reduction of recurrent spontaneous abortion. J Steroid Biochem Mol Biol. 97:431–4. http://dx.doi.org/10.1016/j.jsbmb.2005.08.007; PMid:16253504

23. MacDonald RR, Goulden R, Oakey RE. 1972. Cervical mucus, vaginal cytology and steroid excretion in recurrent abortion. Obstet Gynecol. 40:394–402. PMid:4560047

24. Kumar A, Begum N, Prasad S et al. 2014. Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, parallel, placebo-controlled trial. Fertil Steril 102:1357–1363. http://dx.doi.org/10.1016/j.fertnstert.2014.07.1251; PMid:25241364